Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...
Novo Nordisk’s CEO has insisted that plans to launch the GLP-1/amylin combo treatment CagriSema remain on track, despite the pharma ending hopes of delivering the therapy in a single-chamber device.
LONDON/COPENHAGEN, May 7 (Reuters) - Early data from weight-loss pills are lifting shares in Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab as investors bet that easier-to ...
On April 14, Novo Nordisk announced that it had entered into a partnership with OpenAI. The two companies will collaborate to bring cutting-edge artificial intelligence (AI) capabilities to the drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results